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Methods In this multicentre randomized controlled clini-
cal trial, 100 patients affected by symptomatic chondral and 
osteochondral lesions were treated and evaluated for up to 
2 years (51 study group and 49 control group). A biomimetic 
coll-HA scaffold was studied, and bone marrow stimulation 
(BMS) was used as reference intervention. Primary efficacy 
measurement was IKDC subjective score at 2 years. Sec-
ondary efficacy measurements were: KOOS, IKDC Knee 
Examination Form, Tegner and VAS Pain scores evaluated 
at 6, 12 and 24 months. Tissue regeneration was evaluated 
with MRI MOCART scoring system at 6, 12 and 24 months. 
An external independent agency was involved to ensure data 
correctness and objectiveness.
Results A statistically significant improvement of all 
clinical scores was obtained from basal evaluation to 2-year 
follow-up in both groups, although no overall statistically 
Abstract 
Purpose The increasing awareness on the role of subchon-
dral bone in the etiopathology of articular surface lesions 
led to the development of osteochondral scaffolds. While 
safety and promising results have been suggested, there 
are no trials proving the real potential of the osteochondral 
regenerative approach. Aim was to assess the benefit pro-
vided by a nanostructured collagen–hydroxyapatite (coll-
HA) multilayer scaffold for the treatment of chondral and 
osteochondral knee lesions.
Elizaveta Kon and Giuseppe Filardo: these authors equally 
contributed to this manuscript.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00167-017-4707-3) contains supplementary 
material, which is available to authorized users.
 * Giuseppe Filardo 
 g.filardo@biomec.ior.it
 Elizaveta Kon 
 elisaveta.kon@gmail.com
 Mats Brittberg 
 mats.brittberg@telia.com
 Maurizio Busacca 
 maurizio.busacca@ior.it
 Vincenzo Condello 
 vincenzo.condello@sacrocuore.it
 Lars Engebretsen 
 lars.engebretsen@ioks.uio.no
 Stefan Marlovits 
 office@marlovits.at
 Philipp Niemeyer 
 phniemeyer@gmail.com
 Patrik Platzer 
 patrick.platzer@meduniwien.ac.at
 Michael Posthumus 
 mposthumus@me.com
 Peter Verdonk 
 pverdonk@yahoo.com
 Renè Verdonk 
 rene.verdonk@ugent.be
 Jan Victor 
 jan.victor@ugent.be
 Willem van der Merwe 
 willem@grucox.com
 Wojciech Widuchowski 
 sportmed@sportmed.com.pl
 Claudio Zorzi 
 claudio.zorzi@sacrocuore.it
 Maurilio Marcacci 
 maurilio.marcacci@gmail.com
 Knee Surg Sports Traumatol Arthrosc
1 3
significant differences were detected between the two treat-
ments. Conversely, the subgroup of patients affected by deep 
osteochondral lesions (i.e. Outerbridge grade IV and OCD) 
showed a statistically significant better IKDC subjective out-
come (+12.4 points, p = 0.036) in the coll-HA group. Statis-
tically significant better results were also found for another 
challenging group: sport active patients (+16.0, p = 0.027). 
Severe adverse events related to treatment were documented 
only in three patients in the coll-HA group and in one in the 
BMS group. The MOCART score showed no statistical dif-
ference between the two groups.
Conclusions This study highlighted the safety and poten-
tial of a biomimetic implant. While no statistically signifi-
cant differences were found compared to BMS for chondral 
lesions, this procedure can be considered a suitable option 
for the treatment of osteochondral lesions.
Level of evidence I.
Keywords Osteochondral · Cartilage · Scaffold · Knee · 
Bone marrow stimulation
Introduction
Chondral and osteochondral lesions are debilitating condi-
tions that, if not properly treated, may lead to the develop-
ment of osteoarthritis, with a high impact on patients and 
society, both in terms of healthcare and workforce loss [14, 
15]. The greater emphasis on physical activity in all age 
groups is responsible for the growing incidence of these 
lesions, and concomitantly, patient expectations about func-
tion recovery have risen as well. Thus, in the attempt to fulfil 
patients’ expectations and successfully treat this pathology, 
several techniques have been developed over the years [26].
The available surgical options range from simple strate-
gies such as microfracture (MF) or subchondral drilling to 
the more ambitious regenerative approaches. MF is a bone 
marrow stimulation (BMS) technique aimed at recruiting 
bone marrow cells by creating a communication between 
cartilage lesions and subchondral bone, thus allowing stem 
cells to migrate to the fibrin clot of the defect and form a 
fibrocartilaginous repair tissue [36]. Regenerative proce-
dures aim at recreating a hyaline-like tissue as similar as 
possible to the physiological one, and they are emerging as 
a potential therapeutic option also in cases of large lesions, 
where other procedures are less indicated [1, 32]. Several 
materials have been developed in the attempt to meet the 
requirements of cartilage regeneration. The rationale for 
using a scaffold is to offer a temporary 3-dimensional struc-
ture of biodegradable polymers to mimic cartilage archi-
tecture and favour cell growth [24]. However, despite the 
increasing number of publications every year confirming 
good outcomes also at midterm evaluations [1], the supe-
riority of this technique versus BMS has not been clearly 
proven, and MF is still considered the gold standard that 
sets the reference point to measure the potential of new pro-
cedures [8].
The increasing awareness on the role of subchondral bone 
in the etiopathology of articular surface lesions may explain 
the limits of the current regenerative procedures, which have 
been developed to target only the chondral layer [9, 24]. 
Subchondral bone may be involved in the pathological pro-
cess not only primarily, such as in osteochondritis dissecans 
(OCD), osteonecrosis and trauma, but also secondarily in 
degenerative cartilage lesions. In fact, even focal chondral 
defects, if left untreated, may increase in size over time 
and cause changes of the underlying subchondral bone [25, 
33]. Thus, a surgical approach for both cartilage and bone 
reconstruction that would address articular surface lesions 
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by restoring the properties of the entire osteochondral unit 
should be considered. Among the many different multilayer 
scaffolds developed to reproduce both bone and cartilage 
[35], only a few have been investigated in clinical studies 
[22]. While safety and promising results have been sug-
gested [21, 22], there are no trials proving the real potential 
of the osteochondral regenerative approach compared to the 
gold standard in clinical practice.
The aim of this study is to assess the benefit provided by 
a nanostructured collagen-hydroxyapatite (coll-HA) multi-
layer scaffold in a randomized controlled trial. The hypoth-
esis is that this comparative evaluation will demonstrate 
safety and a superior clinical benefit of this osteochondral 
scaffold.
Materials and methods
The study was performed in compliance with the protocol 
and in accordance with the Declaration of Helsinki, the 
International Conference of Harmonization Guidelines 
for Good Clinical Practice, standards from International 
Organization for Standardization (ISO) and valid inter-
national and national regulations. Patients referring to 
specialized orthopaedic centres in the following countries 
were included: Italy, Sweden, Belgium, Switzerland, Aus-
tria, Germany, Norway, Poland, South Africa. From 2011 to 
2013, 145 patients affected by chondral and osteochondral 
knee lesions were screened; 124 patients were randomized 
(safety population).
The selected ITT population consisted of 118 patients, 
while the PP population resulted in 100 patients, due to 
protocol violators and dropouts (Fig. 1). Study and BMS 
group presented, respectively, a mean age of 34.0 ± 10.9 
and 35.2 ± 10.2 years old; a male/female ratio of 36/15 and 
31/18; a body mass index of 25.6 ± 3.3 and 25.2 ± 3.2 and 
a mean defect size of 3.4 ± 1.5 and 3.5 ± 1.6 cm2. Further 
demographics data have been reported in detail in Table 1. 
These patients were evaluated for up to 2 years of follow-up 
with both clinical and imaging examination.
Patients were randomly allocated to either the scaffold 
or BMS treatment with a ratio of 1:1. The randomization 
list was prepared using the algorithm of Moses Oakford, 
with allocation blocks of variable sizes and stratified by 
orthopaedic centres. In order to minimize possible selec-
tion biases, the randomization code was kept in a sealed 
individual patient envelope, which could be opened only 
just before surgery.
Fig. 1  Flow chart: diagram of 
the patients eligible, rand-
omized, ITT population and PP 
population
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Treatments
MaioRegen (Fin-Ceramica Faenza S.p.A., Italy) is a biocer-
amic composite scaffold, developed to promote the processes 
of tissue regeneration in case of severe and large chondral 
(grade III and IV according to Outerbridge classification) and 
osteochondral lesions, which would otherwise be difficult 
to treat. The design of this 6-mm-thick scaffold mimics the 
three-dimensional natural structure of both cartilage and sub-
chondral bone layers: the cartilaginous upper layer is smooth 
on the surface and consists entirely of Type I equine collagen; 
the intermediate layer is made of a combination of Type I col-
lagen (60%) and magnesium-enriched HA (Mg-HA; 40%), 
while the lower layer consists of a mineralized blend of Type 
I collagen (30%) and Mg-HA (70%). The surgical procedure 
was performed with the patient in supine position with a pneu-
matic tourniquet placed on the proximal thigh. An arthroto-
mic approach with a medial or lateral parapatellar arthrotomy 
was used to expose the lesions. The defect was then prepared 
by removing the sclerotic subchondral bone to obtain stable 
shoulders to house the scaffold, which was implanted by 
press fit according to the previously described technique [17] 
(Fig. 2). After implantation, management of post-operative 
pain allowed for early mobilization starting on the second 
post-operative day to favour swelling resolution, promote 
defect healing and prevent adhesions. Early isometric and 
isotonic exercises and electrical neuromuscular stimulation 
(NMES) were indicated and could be started at patient dis-
charge. By the fourth week, weight touchdown with crutches 
was allowed, and the patient could then move progressively 
towards full weight bearing. Swimming and cycling were 
allowed 1 month after surgery, low active functional training 
after 4–6 months and joint impact activities after 1 year, fol-
lowing previous literature indications [17].
Reference treatment
BMS techniques, such as subchondral drilling or MF, are 
based on the arthroscopic perforation of the subchondral 
bone plate at the bottom of the cartilage lesion, allowing 
stem cells from the bone marrow to repopulate and fill the 
defect with a repair tissue. These methods differ in terms of 
penetration in the subchondral bone plate, with MF being 
the less invasive approach and subchondral drilling entail-
ing deeper holes.
Thus, MF was used for smaller lesions, according to the 
literature indications and with standard Steadman awls [26, 
29], while for lesions larger than 4 cm2 or with a higher 
damage of the subchondral bone, such as OCD, subchondral 
drilling with a Kirschner wire (1.0–1.2 mm in diameter, with 
penetration left to the surgeon judgment in order to reach 
the proper depth and ensure enough bleeding and access to 
Table 1  Demographics of the coll-HA and BMS groups
Coll-HA BMS
Patients 51 49
Age (years) Mean ± SD 34.0 ± 10.9 35.2 ± 10.2
Gender n (%) Male 36 (70.6%) 31 (63.3%)
Female 15 (29.4%) 18 (36.7%)
BMI (kg/m2) Mean ± SD 25.6 ± 3.3 25.2 ± 3.2
Lesion dimension 
 (cm2)
Mean ± SD 3.4 ± 1.5 3.5 ± 1.6
Lesion localiza-
tion n (%)
Condyle 37 (72.6%) 23 (47.0%)
Trochlea 2 (3.9%) 6 (12.2%)
Patella 12 (23.5%) 20 (40.8%)
Aetiology n (%) Microtraumatic/
degenerative
20 (39.2%) 24 (49%)
OCD 15 (29.4%) 12 (24.5%)
Traumatic 13 (25.5%) 12 (24.5%)
Other 3 (5.9%) 1 (2%)
Associated sur-
gery n (%)
19 (37.3%) 14 (28.6%)
Previous surgery 
n (%)
27 (52.9%) 23 (46.9%)
Pre-surgery activ-
ity level n (%)
Non-active 35 (68.6%) 38 (77.5%)
Sport active 16 (31.4%) 11 (22.5%)
Fig. 2  Osteochondral scaffold 
implantation for a traumatic 
focal medial femoral condyle 
lesion of 2 cm2 in a 30-year-old 
man
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progenitor cells) was chosen to ensure the highest chances 
of success for patients randomized to the BMS approach.
Outcome measures
Efficacy was evaluated according to the following widely 
accepted outcome measurements. Primary criteria: IKDC 
Subjective Knee Evaluation Form 2000 score 2 years after 
surgery, as proposed by the ICRS (International Cartilage 
Repair Society) [16]. Secondary criteria: patient functional 
improvement through KOOS, IKDC Knee Examination Form 
2000, Tegner scores [7, 16, 38] evaluated at each follow-
up visit, together with patient pain assessment (VAS Pain). 
Tissue regeneration was evaluated at each follow-up visit 
with 1.5-T MRI. All post-operative MRIs were centrally and 
blindly evaluated by senior musculoskeletal radiologists by 
applying the most commonly accepted score for the evalu-
ation of cartilage treatments (MOCART scoring system) 
[28], modified to assess the subchondral bone health state 
(supplementary material). For the detailed description of the 
sequences used and the parameters evaluated see supplemen-
tary material. Each MRI was evaluated by two radiologists; 
in case of discrepancy of the result, a third radiologist was 
involved.
Safety was evaluated focusing on the number and type of 
adverse events after surgery (pain, movement restriction, infec-
tion, inflammation, device expulsion or mobilization, etc.). 
Failure was defined as the need for reintervention on the same 
defect based on the persistence or recurrence of symptoms.
An external independent agency (Contract Research 
Organization, CRO) was involved to ensure data correctness 
and objectiveness of the study results. In particular, planning 
and investigation were performed according to the Standard 
Operating Procedures of CROMSOURCE (Verona, Italy) 
to ensure the protection of the rights and the integrity of the 
subjects, adequate and correct conduct of all study proce-
dures, data collection, documentation and data verification.
The trial, coordinated by the Rizzoli Orthopaedic Insti-
tute (Bologna, Italy), was approved by the local hospital and 
regional ethics committees, and written informed consent of 
all patients was obtained before enrolment (Prot. 0020721 
Trial registration: NCT01282034).
Statistical analysis
A blinded statistician carried out the analysis.
In order to minimize the influence of the protocol violators 
on the results and the possible bias of focusing on ITT popu-
lations in surgical studies, by ignoring patient noncompliance 
with the original assignment, it was deemed opportune to 
focus further analysis on the PP population. This population, 
free of carryover effects (dropouts) and of major protocol 
violations (pre-specified before unblinding), is more reli-
able as it consists of patients who adhered perfectly to the 
clinical trial instructions as stipulated in the protocol. Con-
sequently, results on the PP population would more likely 
exhibit the effects of treatment according to the underlying 
scientific model. The comparative analysis is based on an 
ANCOVA model with change from baseline to 2-year follow-
up in IKDC Subjective Knee Evaluation score as dependent 
variable, treatment, centre and location as fixed effects and 
baseline as covariate. Results of the primary analysis are pre-
sented as a point estimate, a 95% confidence interval and an 
associated p value for the adjusted mean difference between 
coll-HA and BMS groups, for the PP population.
Sample size: the study was designed to demonstrate the 
superiority of coll-HA scaffold compared to BMS tech-
niques. The null hypothesis for the treatment comparison 
was that there would be no difference between coll-HA (test) 
and BMS techniques (reference). The alternative hypothesis 
was that there would be a difference. A two-sided t test with 
α = 0.05 was used to test this hypothesis. Based on the evi-
dence from the pilot study [17], and assuming seven points 
as the minimum acceptable difference in the modification of 
the IKDC Subjective Knee Evaluation Score between coll-
HA and BMS therapy, the sample size for every group in the 
study was estimated in 67 patients, in order to ensure a power 
equal to 90% and a first type error alpha of 5%. From 2011 to 
2013, 145 patients were screened and 124 randomized. Due 
to protracted enrolment period and after an interim analysis, 
it was decided to interrupt the study once 118 treated patients 
were reached (ITT population). Excluding major violators 
and dropouts, the PP population consisted in 100 patients 
who were treated and evaluated for up to 2 years of follow-up 
(51 study group and 49 BMS group) (Fig. 1).
Results
A statistically significant improvement of all clinical scores 
was obtained from baseline to 2-year follow-up in both treat-
ment groups.
Coll‑HA group
The IKDC subjective VAS Pain, Tegner and KOOS scores, 
as well as the percentage of patients with “Normal” or 
“Nearly normal” knees, improved as detailed in Tables 2, 
3 and Fig. 3. In this group, one centre had a statistically 
significant worse performance when compared to others 
(p < 0.05). Nevertheless, it was decided to maintain the cen-
tre in the statistical analyses since no errors were observed 
in the management of the study.
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BMS group
The IKDC subjective, VAS Pain, Tegner and KOOS scores 
improved, as detailed in Table 2 and Fig. 3. There was no 
statistically significant difference from baseline to 2-year fol-
low-up in the percentage of patients with “Normal” or “Nearly 
normal” outcome according to the IKDC Knee Examination 
Form changed (Table 3).
Comparison between coll‑HA group and BMS group
The comparative analysis showed no statistically signifi-
cant difference in IKDC subjective score at 2-year follow-
up between the two treatment groups. Similarly, the overall 
outcome measured with VAS Pain, KOOS, IKDC Knee 
Examination Form and Tegner scores did not show any sta-
tistically significant difference.
Imaging evaluation
With regard to the imaging evaluation of tissue regenera-
tion, the MOCART score showed no statistical difference 
in the MRI score between the two groups. In the coll-HA 
Table 2  Outcome evaluations pre-operatively, at 1 and 2 years of follow-up
p value* on adjusted mean difference between treatments (coll-HA–BMS)
Bold values indicate statistical significance
The values are given as a the mean with standard deviation or b median and range in parentheses
Coll-HA BMS
Pre-op. 
(mean ± SD)/
median (range)
1 year 
(mean ± SD)/
median (range)
2 years
(mean ± SD)/
median 
(range)
Pre-op.
(mean ± SD)/
median 
(range)
1 year
(mean ± SD)/
median 
(range)
2 years
(mean ± SD)/
median 
(range)
Adjusted mean 
difference 
between treat-
ments
p value*
Subj.  IKDCa
Total 43.2 ± 16.6 60.7 ± 17.3 66.7 ± 21.0 41.1 ± 15.9 61.8 ± 18.0 63.6 ± 18.2 −0.482 n.s.
Deep osteo-
chondral 
lesions
42.4 ± 17.5 66.8 ± 15.3 77.8 ± 15.6 38.9 ± 12.9 60.0 ± 16.6 64.3 ± 18.1 12.437 0.036
Sport active 
patients
50.1 ± 15.4 68.2 ± 19.0 76.3 ± 20.4 44.5 ± 20.5 63.1 ± 16.4 64.2 ± 15.9 15.946 0.027
OCD 50.3 ± 18.8 71.3 ± 16.3 76.7 ± 18.8 36.4 ± 9.7 59.5 ± 14.7 61.9 ± 18.0 11.946 n.s.
VAS–Paina 50.1 ± 26.7 23.8 ± 20.8 26.5 ± 27.5 53.1 ± 22.7 29.2 ± 23.2 23.2 ± 20.9 6.553 n.s.
Tegnerb 3.0
(0.0; 7.0)
4.0
(2.0; 7.0)
4.0
(1.0; 9.0)
3.0
(0.0; 9.0)
4.0
(1.0; 9.0)
4.0
(2.0; 8.0)
0.139 n.s.
Table 3  Final evaluation from 
IKDC Knee Examination Form 
from pre-operatively to 1 and 
2 years of follow-up
Coll-HA BMS
Pre-op. (%) 1 year (%) 2 years (%) Pre-op. (%) 1 year (%) 2 years (%)
Normal 49.0 76.5 80.4 36.7 87.8 73.5
Nearly normal 33.3 17.6 13.7 42.9 10.2 16.3
Abnormal 11.8 3.9 3.9 14.3 0.0 6.1
Severely abnormal 3.9 2.0 0.0 4.1 0.0 0.0
Missing/ND 2.0 0.0 2.0 2.0 2.0 4.1
Fig. 3  Change from baseline to 2-year follow-up of KOOS profile 
(black: coll-HA and grey: BMS)
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population, a reduction in the effusion was observed up to 
2 years and features consistent with ongoing bone remodel-
ling were found. (Details are reported in Table 4, Fig. 4.)
Adverse events
Safety was evaluated focusing on number and type of 
adverse events after surgery in all patients randomized 
Table 4  MOCART score
Coll-HA BMS
6 months 1 year 2 years 6 months 1 year 2 years
n = 45 pts 
(%)
n = 49 pts 
(%)
n = 51 pts 
(%)
n = 43 pts 
(%)
n = 45 pts 
(%)
n = 44 pts 
(%)
Degree of defect repair and filling of the defect
  Complete 53.3 40.8 49.0 39.5 55.6 65.9
  Hypertrophy 33.3 36.7 37.3 18.6 13.3 18.2
  Incomplete, >50% of the adjacent cartilage 8.9 20.4 13.7 34.9 31.1 11.4
  Incomplete, <50% of the adjacent cartilage 2.2 2.0 0.0 4.7 0.0 2.3
  Subchondral bone exposed 2.2 0.0 0.0 2.3 0.0 2.3
Integration to border zone
  Complete 40.0 61.2 60.8 53.5 60.0 70.5
  Incomplete, demarcating border visible 48.9 30.6 37.3 32.6 35.6 22.7
  Incomplete, defect visible, <50% 8.9 8.2 2.0 7.0 4.4 4.5
  Incomplete, defect visible, >50% 2.2 0.0 0.0 7.0 0.0 2.3
Surface of the repair tissue
  Surface intact 48.9 49.0 56.9 46.5 62.2 56.8
  Surface damaged, < 50% 42.2 46.9 41.2 44.2 35.6 40.9
  Surface damaged, > 50% 8.9 4.1 2.0 9.3 2.2 2.3
Structure of the repair tissue
  Homogeneous 8.9 16.3 13.7 55.8 46.7 45.5
  Inhomogeneous or cleft formation 91.1 83.7 86.3 44.2 53.3 54.5
Signal intensity of the repair tissue–dual T2-FSE
  Isointense 26.7 24.5 41.2 55.8 64.4 61.4
  Moderately hyper-/hypo-intense 66.7 73.5 56.9 39.5 35.6 36.4
  Markedly hyper-/hypo-intense 6.7 2.0 2.0 4.7 0.0 2.3
Signal intensity of the repair tissue—DP FAT-SAT
  Isointense 26.7 18.4 43.1 41.9 48.9 47.7
  Moderately hyper-/hypo-intense 60.0 75.5 52.9 51.2 48.9 47.7
  Markedly hyper-/hypo-intense 13.3 6.1 3.9 7.0 2.2 4.5
Subchondral bone
  Intact 44.4 24.5 11.8 41.9 42.2 25.0
  Minimal changes 51.1 69.4 70.6 51.2 48.9 65.9
  Marked changes 4.4 6.1 17.6 7.0 8.9 9.1
Oedema
  Absent 35.6 42.9 43.1 30.2 35.6 52.3
  Slightly hyperintense and/or small oedema 62.2 51.0 49.0 65.1 57.8 40.9
  Markedly hyperintense and/or extensive oedema 2.2 6.1 7.8 4.7 6.7 6.8
Adhesions
  No 100 100 100 100 100 100
Effusion
  No 28.9 40.8 62.7 67.4 71.1 68.2
  Yes 71.1 59.2 37.3 32.6 28.9 31.8
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and treated (124 patients). Severe treatment-related 
adverse events were documented in 3 patients in the coll-
HA group and in 1 patient in the BMS group. Two failures 
were detected in the study group. (Details of all safety-
related events are reported in Table 5.)
Predicting factors influencing the final outcome
In the group treated with coll-HA, factors predicting a 
favourable or a negative outcome were: Outerbridge grade 
IV (factor predicting positive outcome: p < 0.05) and con-
comitant ACL treatment (factor predicting negative out-
come: p < 0.05), while other parameters such as age, sex and 
lesion size did not influence the final outcome. No predicting 
factors were present in the BMS group.
Further analyses were performed to identify whether spe-
cific patients’ subgroups (chosen according to factors found 
to influence coll-HA results and to scientific literature) may 
present more or less benefit compared to the applied treat-
ments. Accordingly, patients affected by deep osteochon-
dral lesions (patients suffering from osteochondral lesions 
severely involving subchondral bone, i.e. Outerbridge 
grade IV and OCD) with no associated ACL surgery were 
identified as group of interest. This subgroup included 27 
patients treated with coll-HA and 30 with BMS; the analy-
sis showed statistically higher values in terms of adjusted 
means of changes from baseline to 2 years: 33.6 (95% CI) for 
coll-HA vs 21.2 (95% CI) for the BMS group at 2 years of 
follow-up. Change from baseline to 2 years in IKDC Subjec-
tive Knee Evaluation score showed a statistically significant 
(p = 0.036) adjusted mean difference of +12.4 points in 
favour of coll-HA (Table 2, Fig. 5).
A superior outcome was also found for the sport active 
patients’ subgroup (16 patients in the coll-HA group and 11 
in the BMS group), with a statistically higher (p = 0.027) 
Fig. 4  Magnetic resonance 
imaging evaluation of a coll-HA 
implant in the medial femoral 
condyle, showing ongoing 
osteochondral remodelling 
at 6 months, 1 and 2 years of 
follow-up
Table 5  Safety evaluation of coll-HA and BMS groups
Coll-HA BMS
Safety population 62 patients 62 patients
No. of adverse events related:
 Minor early post-operation symptoms
 Inflammation
 Joint adhesions
 Persistent pain
 Loose body
 Joint instability
13 (total)
8
3
1
1
0
0
4 (total)
3
0
0
0
0
1
No. of serious adverse events related:
 Joint adhesions
 Persistent pain
 Loose body
3 (total)
2
1
0
1 (total)
0
0
1
No. of failures 2 0 Fig. 5  Change from baseline to 2-year follow-up of IKDC Subjec-tive Knee Evaluation score in deep osteochondral lesions subgroup 
(black: coll-HA and grey: BMS)
Fig. 6  Change from baseline to 2-year follow-up of IKDC Subjective 
Knee Evaluation score in sport active patients’ subgroup (black: coll-
HA and grey: BMS)
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adjusted IKDC subjective mean difference of +16.0 points 
in favour of coll-HA at 2-year follow-up (Table 2, Fig. 6).
Finally, in the subgroup of patients affected by OCD (15 
patients treated with coll-HA and 12 with BMS), there was a 
clinically relevant improvement in patients treated with coll-
HA. Change from baseline to 2-year follow-up in IKDC Sub-
jective Knee Evaluation score showed an adjusted mean dif-
ference of +12.0 points between the two treatments, which 
is clinically meaningful although not statistically significant 
in this study (p = 0.144) (Table 2, Fig. 7).
Discussion
The main finding of this study is that comparable results 
were found in the overall population, whereas the coll-HA 
osteochondral scaffold offered significant clinical better 
results compared to BMS in the treatment of osteochondral 
lesions. BMS techniques confirm to be a treatment option 
for purely chondral lesions, but offer worse results for more 
complex lesions, where the biomimetic scaffold, designed 
to address also the subchondral area, showed to be a more 
suitable therapeutic solution.
The reason for this selected superiority lies in the rational 
of the treatments themselves, and the mechanisms leading 
to these different results reflect previous literature findings. 
Smaller chondral lesions are those benefiting more from 
BMS, whose potential to achieve good results over time 
finds the main limitation in the lesion size [13]. In fact, the 
repair tissue response is often fibrous and cannot address 
successfully larger defects [31]. This, together with the dam-
age produced by the technique at the subchondral bone level 
[30], may explain the inferior results obtained with BMS 
in more complex lesions. On the other hand, the compos-
ite scaffold has been developed to mimic the biochemical 
and biophysical properties of different layers of the native 
osteochondral structure [37] to favour the repair of the entire 
osteochondral unit [34]. The properties of this scaffold have 
been shown to produce good results in preclinical models 
[23, 34]. The scaffold ability to induce an in situ repair 
through cells coming from the surrounding bone marrow in 
the animal model [18] allowed to introduce it in the clinical 
practice as a cell-free approach.
Safety and preliminary experiences with human appli-
cation have been documented in case series published by 
different groups. Delcogliano et al. obtained an encourag-
ing outcome at 24-month follow-up on 19 patients affected 
by large-sized defects [5], confirmed by Verdonk et al. 
evaluating at the same follow-up 38 patients affected by 
osteochondral lesions [39]. These positive findings were 
also confirmed by Berruto et al. evaluating 49 patients 
in a multicentre study which supported the potential of 
this scaffold also for the treatment of large osteochondral 
lesions [2]. This biomimetic scaffold was also tested as 
salvage procedure in young patients for the treatment of 
unicompartmental OA, where subchondral cysts, oedema 
and stiffening may be addressed by the osteochondral scaf-
fold, an attempt to provide an alternative solution to metal 
resurfacing that showed promising short-term results [12, 
27]. Finally, some encouraging findings have also been 
documented in the only available comparative evaluation 
versus a chondral scaffold for the treatment of complex 
lesions, with a better outcome in the osteochondral treat-
ment group [11].
This multicentre study confirms safety and potential 
of the osteochondral scaffold, showing for the first time, 
with a randomized study design, the improvement pro-
vided compared to BMS when targeting complex osteo-
chondral knee lesions. This benefit is supported by the 
clinical outcome documented through a subjective func-
tional evaluation. More adverse events were reported in 
the study group. However, most of them were minor post-
op symptoms that spontaneously resolved within 45 days. 
The higher rate of adverse events may be explained by 
the different invasiveness of coll-HA and BMS surgical 
approaches, i.e. arthrotomic versus arthroscopic, which 
have been shown to affect the early recovery of the patients 
[19]. Summarizing, this trial shows how to address the 
entire osteochondral unit and the usefulness of this bio-
mimetic implant.
Nonetheless, the imaging evaluation confirms some con-
cerns previously risen in the literature on the slow restora-
tion of the subchondral bone area. Even though the slow 
bone mineralization did not correlate with a lower clinical 
outcome, their significance and impact in terms of tissue 
regeneration and clinical outcome remains to be deter-
mined. Suboptimal imaging findings, not correlating with 
clinical results, have been shown at short-term evaluation by 
Verdonk et al. and Christensen et al. in particular in terms 
of subchondral bone formation [2, 4]. On the other hand, 
Fig. 7  Change from baseline to 2-year follow-up of IKDC Subjective 
Knee Evaluation score in OCD subgroup (black: coll-HA and grey: 
BMS)
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Brix et al. underlined a limited cartilage quality but a suc-
cessful osteoconduction [3]. While further studies need to 
explore the clinical impact of the observed alterations, the 
only available midterm evaluation of this osteochondral 
scaffold shows stable clinical results, as well as a signifi-
cant MRI improvement between 2 and 5 years of follow-up 
[20]. This may suggest that the maturation required by an 
osteochondral scaffold may be longer than what expected 
for chondral scaffolds (as confirmed by this RCT). This is 
probably due to the greater complexity of a scaffold aiming 
at restoring the entire osteochondral unit and also by the 
bigger size of the tissues integrating and regenerating, being 
not just a thin layer but rather a thick layer of articular sur-
face. Moreover, controversial findings may be also partially 
explained by MRI itself, which in a recent meta-analysis was 
shown to fail a correlation in the majority of the parameters 
observed, with only 28% of the studies presenting a correla-
tion between MRI and treatment outcomes [6]. Since the 
scores available for cartilage studies were designed for the 
evaluation of cartilage treatments, it is easy to understand 
that it is even more difficult to expect a correlation in case 
of an osteochondral treatment evaluation. Therefore, caution 
should be recommended when interpreting MRI findings and 
greater importance should be placed on the patient clinical 
evaluation, until more reliable imaging instruments will be 
available.
This study presents some limitations. The number of 
originally planned patients has not been reached, which 
could have hampered the possibility to detect further sig-
nificant differences. Nonetheless, the study groups allowed 
to document the superiority of the osteochondral scaffold 
in deep osteochondral lesions, which is in line with pre-
vious preliminary literature findings [11] and what one 
may expect from an osteochondral biomimetic implant. 
Patients were rather heterogeneous in terms of age, lesion 
dimension, location and aetiology, and one-third required 
combined surgeries. This, on the one hand, may represent 
a confounding factor, but it also allows to have a study 
population more representative of the general population 
commonly requiring cartilage treatments, which increases 
the generalizability of these study findings. Despite its het-
erogeneity, a tendency to treat small lesions was observed 
in this study, and this might have entailed a bias in favour 
of the BMS group, as it is possible that coll-HA yields 
more favourable results in bigger lesions, while MF is 
more suitable for smaller lesions. Thus, the superiority 
found for complex lesions regardless of this limitation 
further confirms the potential of this scaffold. The study 
presents also other limitations: the 2-year follow-up does 
not allow to detect the outcome decline of BMS shown 
by previous literature [8, 13], neither to understand the 
clinical meaning and evolution of the abnormal MRI find-
ings observed in the scaffold implant area, which warrants 
further evaluation at longer follow-up. To this regard, 
the only study currently available at midterm follow-up 
showed stable clinical outcome and a trend towards slow 
imaging improvement, even though MRI abnormalities 
persisted even at 5-year follow-up [20]. The understand-
ing of the tissue and clinical evolution over time is there-
fore particularly important because it could allow to better 
identify both treatment potential and most suitable indica-
tions. In fact, many questions remain still open, athletes 
tend to present good early results with several procedures, 
thus the benefit shown in this study should be confirmed 
by longer-term evaluations, and it will be important to 
understand whether bone repair, which may explain the 
better results in osteochondral lesions, is coupled by suf-
ficient cartilage repair in order to allow good and stable 
results overtime in young active patients.
Future studies should therefore focus on osteochondral 
healing mechanisms and on further improvement of the 
regenerative potential of this scaffold. To this regard, tech-
nical advancements have been already identified, such as 
the possibility to enhance the scaffold fixation with the 
use of fibrin glue or to use thinner scaffolds for shallower 
lesions, thus prompting the possibility to further increase 
the outcome of the scaffold [10]. Moreover, while preclini-
cal evaluations did not show any benefit in chondrocyte 
seeding [18], further studies should explore whether other 
augmentation strategies could improve the osteochondral 
regenerative potential either with chondro/osteoinductive 
molecules or taking advantages from the combination with 
other cell sources to promote a faster healing with a higher 
quality tissue and in the end better clinical results.
While the clinical applicability of the aforementioned 
augmentation procedures may be affected by economic and 
regulatory requirements, this study highlighted the safety 
and potential of the biomimetic coll-HA implant show-
ing, for the first time with a randomized trial, its superior-
ity versus BMS approach in the treatment of osteochon-
dral defects. Thus, this procedure can be considered as 
an option to address the damaged articular surface when 
subchondral bone is also involved, with the advantage of 
being an off-the-shelf product requiring a one-step surgery 
and offering good results for the treatment of the osteo-
chondral surface.
Conclusions
This RCT showed safety and an overall positive clinical 
outcome provided by this coll-HA biomaterial. While 
comparable results were found in the overall popula-
tion, the osteochondral scaffold offered significant clin-
ical better results compared to BMS in the treatment 
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of osteochondral lesions. BMS techniques confirm to 
be a treatment option for purely chondral lesions, but 
offer worse results for more complex lesions, where the 
biomimetic scaffold, designed to address also the sub-
chondral area, showed to be a more suitable therapeutic 
solution.
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